Welcome to our dedicated page for Alkermes Plc SEC filings (Ticker: ALKS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a 250-page biotech filing while tracking clinical milestones for Vivitrol, Aristada and Lybalvi can consume your entire day. Alkermes’ disclosures blend scientific detail with complex revenue recognition rules, leaving many investors searching line by line for what matters most.
Stock Titan solves this problem by coupling real-time EDGAR feeds with AI-powered summaries that turn technical language into plain English. Whether you need the Alkermes quarterly earnings report 10-Q filing or an Alkermes annual report 10-K simplified, our system highlights trial updates, segment revenue, and key risk factors in seconds. You’ll also receive instant alerts on every Alkermes insider trading Form 4 transactions entry—so you can monitor Alkermes executive stock transactions Form 4 before market reactions.
Looking for something specific? Our platform answers the exact questions professionals ask:
- “How did R&D spend shift this quarter?” — see it in the Alkermes earnings report filing analysis
- “Any new 8-K disclosures?” — check Alkermes 8-K material events explained with one click
- “What’s in the latest proxy?” — explore Alkermes proxy statement executive compensation without scrolling hundreds of pages
Every filing—10-K, 10-Q, 8-K, S-8, and even niche forms—arrives the moment it hits EDGAR, complete with Alkermes Form 4 insider transactions real-time notifications. Use our AI to compare quarter-over-quarter product sales, understand safety-signal language, and evaluate pipeline timelines, all while understanding Alkermes SEC documents with AI. Complex biotech disclosures, finally clear.
T. Rowe Price Associates, Inc. reported beneficial ownership of 10,041,900 shares of Alkermes plc common stock, representing 6.1% of the class as of June 30, 2025. The firm reports sole voting power for 9,983,207 shares and sole dispositive power for 10,041,900 shares on a Schedule 13G/A.
The filing identifies T. Rowe Price as an investment adviser filing under Rule 13d-1(b) and certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The Schedule is signed by Ellen York, Vice President, dated August 14, 2025.
Alkermes (ALKS) Q2-25 10-Q highlights: Net revenue slipped 2% YoY to $390.7 m as a 36% fall in manufacturing & royalty income (-$46.4 m) outweighed a 14% jump in proprietary product sales to $307.2 m. VIVITROL +9% to $121.7 m, ARISTADA franchise +18% to $101.3 m and LYBALVI +18% to $84.3 m.
Earnings & cash: Operating income from continuing ops declined 15% to $93.0 m; diluted EPS fell to $0.52 from $0.55. R&D spending rose 30% to $77.4 m while SG&A was flat. Lower royalties cut gross margin mix but cost-of-goods remained modest at 12.7% of sales. Operating cash flow rose 49% to $249.0 m, lifting cash & equivalents to $521.2 m (vs $291.1 m YE-24); no long-term debt remains, eliminating interest expense.
Balance sheet: Total assets grew to $2.25 bn; equity improved 11% to $1.62 bn. Share count fell 2% YoY to 165.1 m; $200 m of the $400 m buyback authorization is still available.
Key developments: • Royalty stream from long-acting INVEGA products continued to fade after August-24 U.S. expiry. • Medicaid rebate true-ups cut reserves by $30.1 m, aiding cash. • July-25 settlement with Zydus grants first generic VUMERITY entry only immediately prior to patent expiry. • New U.S. patent (12,311,027) extends ARISTADA protection to 2033.
Outlook: Management signals further revenue mix shift toward proprietary brands, higher R&D for pipeline assets (e.g., alixorexton), and materially higher operating cash following recent U.S. tax law changes.
FAQ
What is the current stock price of Alkermes Plc (ALKS)?
What is the market cap of Alkermes Plc (ALKS)?
